PMID- 24284965
OWN - NLM
STAT- MEDLINE
DCOM- 20141015
LR  - 20211021
IS  - 1942-0870 (Electronic)
IS  - 1942-0862 (Print)
IS  - 1942-0862 (Linking)
VI  - 6
IP  - 1
DP  - 2014 Jan-Feb
TI  - Enhancement of anti-tumor CD8 immunity by IgG1-mediated targeting of Fc 
      receptors.
PG  - 108-18
AB  - Dendritic cells (DCs) function as professional antigen presenting cells and are 
      critical for linking innate immune responses to the induction of adaptive 
      immunity. Many current cancer DC vaccine strategies rely on differentiating DCs, 
      feeding them tumor antigens ex vivo, and infusing them into patients. 
      Importantly, this strategy relies on prior knowledge of suitable "tumor-specific" 
      antigens to prime an effective anti-tumor response. DCs express a variety of 
      receptors specific for the Fc region of immunoglobulins, and antigen uptake via 
      Fc receptors is highly efficient and facilitates antigen presentation to T cells. 
      Therefore, we hypothesized that expression of the mouse IgG1 Fc region on the 
      surface of tumors would enhance tumor cell uptake by DCs and other myeloid cells 
      and promote the induction of anti-tumor T cell responses. To test this, we 
      engineered a murine lymphoma cell line expressing surface IgG1 Fc and discovered 
      that such tumor cells were taken up rapidly by DCs, leading to enhanced 
      cross-presentation of tumor-derived antigen to CD8+ T cells. IgG1-Fc tumors 
      failed to grow in vivo and prophylactic vaccination of mice with IgG1-Fc tumors 
      resulted in rejection of unmanipulated tumor cells. Furthermore, IgG1-Fc tumor 
      cells were able to slow the growth of an unmanipulated primary tumor when used as 
      a therapeutic tumor vaccine. Our data demonstrate that engagement of Fc receptors 
      by tumors expressing the Fc region of IgG1 is a viable strategy to induce 
      efficient and protective anti-tumor CD8+ T cell responses without prior knowledge 
      of tumor-specific antigens.
FAU - Furlan, Scott N
AU  - Furlan SN
FAU - Mandraju, Rajakumar
AU  - Mandraju R
FAU - Brewer, Travis
AU  - Brewer T
FAU - Roybal, Kole
AU  - Roybal K
FAU - Troutman, Ty Dale
AU  - Troutman TD
FAU - Hu, Wei
AU  - Hu W
FAU - Palm, Noah W
AU  - Palm NW
FAU - Unni, Arun
AU  - Unni A
FAU - Pasare, Chandrashekhar
AU  - Pasare C
LA  - eng
GR  - T32 AI005284/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - MAbs
JT  - mAbs
JID - 101479829
RN  - 0 (Immunoglobulin G)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Receptors, Fc)
SB  - IM
MH  - Animals
MH  - CD8-Positive T-Lymphocytes/*immunology/metabolism/pathology
MH  - Cell Line, Tumor
MH  - *Immunity, Cellular
MH  - Immunoglobulin G/*immunology/metabolism
MH  - Lymphoma/*immunology/metabolism/therapy
MH  - Mice
MH  - Neoplasm Proteins/biosynthesis/*immunology
MH  - Receptors, Fc/biosynthesis/*immunology
PMC - PMC3929435
EDAT- 2013/11/29 06:00
MHDA- 2014/10/16 06:00
PMCR- 2015/01/01
CRDT- 2013/11/29 06:00
PHST- 2013/11/29 06:00 [entrez]
PHST- 2013/11/29 06:00 [pubmed]
PHST- 2014/10/16 06:00 [medline]
PHST- 2015/01/01 00:00 [pmc-release]
AID - 27052 [pii]
AID - 2013MABS0420R [pii]
AID - 10.4161/mabs.27052 [doi]
PST - ppublish
SO  - MAbs. 2014 Jan-Feb;6(1):108-18. doi: 10.4161/mabs.27052.